Myelodysplastisches Syndrom

Sie befinden sich hier:

STIMULUS-MDS1

EudraCT-#: 2018-004479-11

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS)

Indikation: High or Very High Risk MDS

Ansprechpartner: Dr. med. K. Rieger

IDEAL

EudraCT-#: 2018-001693-25

A Single-Arm Phase II Multicenter Study of IDH2 (AG221) Inhibitor in patients with IDH2 mutated Myelodysplastic Syndrome

Indikation: High or Low Risk MDS

Ansprechpartner: Dr. med. K. Rieger

LUCAS (in Vorbereitung)

EudraCT-#: 2020-003896-20

A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate 1 Risk Myelodysplastic Syndromes (MDS)

Indikation: Low Risk MDS with Anemia and EPO < 200 U/L or ESA refractory MDS

Ansprechpartner: Dr. med. K. Rieger

MDS-M15-954 (in Vorbereitung)

EudraCT-#: 2020-000744-55

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Indikation: Higher Risk MDS; First line

Ansprechpartner: Dr. med. K. Rieger

Nutzen Sie bitte die Übersicht aller Studienaktivitäten der CharitéUniversitätsmedizin Berlin vom Charité Comprehensive Cancer Center (CCCC)